Lexicon Pharma (LXRX) Announces FDA Approval for XERMELO to Treat Carcinoid Syndrome Diarrhea
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELOâ„¢ (telotristat ethyl) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE